



# BRONKOSKOPİDE ANESTEZİ

**Dr. Tülün Öztürk**

*Celal Bayar Üniversitesi Tıp Fakültesi*

*Manisa*

# BRONKOSKOPİDE ANESTEZİ

- Endikasyon- Kontrendikasyon
- Hemodinamik etkiler
- Monitoring
- Lidokain-Atropin
- Hipoksemi
- Sonrası problemler

# BRONKOSKOPİDE ANESTEZİ

- Hava yolunu görüntü eşliğinde değerlendirme.

## TARİHÇE



1847	<u>H. Green</u>	<u>Trakeobronşial ağaç</u>
1897	<u>G. Killan</u>	<u>Endoskop ile yabancı cisim çıkarılması</u> <i>"Direk bronkoskopi"</i>
1900	<u>C. Jackson</u>	<u>Bronş biyopsileri</u>
1960	<u>H. A. Anderson</u>	<u>Parankim biyopsisi</u>
1967	<u>S. Ikeda</u>	<u>Fiberoptik endoskopi</u>

[L'anesthésie en bronchoscopie.](#)

3033- SOULAS A.

Ann Otolaryngol. 1947 Mar-Apr;64(3-4):203-5. Undetermined Language. No abstract available.

PMID: 20264102

[Similar articles](#)



# ANESTEZİDE BRONKOSKOPI

## Ameliyathane

- Zor entübasyon
- Endobronşial tüp doğrulama
- Bronşial blokerler yerleşimi

## Yoğun Bakımda

- Atelektazi
- Trakeostomi yerinin doğrulanması




Figure 2 A view of a patient's carina is seen on the screen of the VivaSight monitor.



# AMELİYATHANE DIŐINDA BRONKOSKOPI



## Bronkoskopi Ünitesi



- Tanısal Amaçlı veya Tedavi Amaçlı

- Virtual Bronkoskopi
- Radial probe EBUS
- Navigasyon bronkoskopi


Vertual veya elektromanyetik navigasyon bronkoskopi

- Ultrathin bronchoscopy
- Floresan bronkoskopi
- Image-guided bronchoscopy techniques

Virtual bronchoscopy



Autofluorescence for recurrent cancer



# TANISAL ya da TEDAVİ AMAÇLI

- ❑ Akciğer tümörleri tanısı, evreleme, tedaviye yanıt
- ❑ Hemoptizi, Öksürük
- ❑ Reküren atelektazi; Endobronşial tm?
- ❑ İnterstisiel akciğer hastalıklarında
- ❑ Yabancı cisim, Karsinoid tümör, Skarlar, (lazer, elektrokoter)
- ❑ Büyük havayolu darlıklarında (stent), bronko-plevral fistül tamir

## Indications for bronchoscopy

### Inspection

Cough (persistent, unexplained)
Hemoptysis
Wheeze (localized/fixed)
Diaphragmatic paralysis*
Unexplained hoarseness and/or vocal cord paralysis/stridor
Suspected tracheo-esophageal fistula
Chest trauma
Suspected tracheomalacia
Toxic inhalation or burn injury
Verify tracheostomy or endotracheal tube placement
Evaluate precancerous lesions (autofluorescence)
Donor transplant lung evaluation

Table 2. Indications of these procedures

Indications	n	%
Indications for diagnostic procedure		
Mass/nodule	10,656	60
Infectious lung disease	3,012	16.9
Cough	2,596	14.7
Pulmonary atelectasis	1,497	8.4
Indications for therapeutic procedure		
Foreign body	756	12.8
Suctioning of sputum	727	12.3
Airway obstruction	2,571	43.4
Airway stenosis	1,867	31.5

# TANISAL ya da TEDAVİ AMAÇLI

<i>Tool</i>	<i>Scope</i>	<i>Complication</i>				<i>Lesion</i>
		<i>Rapid Effect</i>	<i>Repeatable</i>	<i>Immediate</i>	<i>Delayed</i>	
Laser	Rigid/flexible	++++	++++	++	+	Endobronchial
Brachytherapy	Flexible <sup>a</sup>	+	+	+	+++	Endobronchial/submucosal
Cryotherapy	Rigid/flexible	++	++++	++	++	Endobronchial
Balloon dilation	Rigid/flexible	++++	++++	+++	+	Submucosal/external compression
Photodynamic therapy	Flexible <sup>a</sup>	++	+++	+	+++	Endobronchial/submucosal
Electrocautery	Rigid/flexible	+++	++++	++	++	Endobronchial
Stent	Rigid/flexible <sup>b</sup>	++++	+++	++	+++	External compression

# ANESTEZİYOLOG DESTEĞİNİ GEREKTİREN DURUMLAR

## HASTA

1. Yüksek ASA
2. Düşük SpO2
3. Çocuk hasta

## HAVAYOLU

1. Santral havayolu obstruksiyonu
2. Ciddi hemoptizi
3. SY riski

## ANESTEZİYOLOG

## İŞLEM

1. Rijit bronkoskopi
  2. EBUS-TBNA;
  3. Tm. evreleme
- GENEL ANESTEZİ**




# ANESTEZİYOLOGDAN BEKLENEN

- ❑ Hasta- Uygulayıcı **KONFORU**
  - Kötü deneyim
  - Ajitasyon
  - Öksürük
- ❑ Güvenli hava yolu, yeterli oksijenasyon
- ❑ İşlem sonrası hızla geri dönen, MV desteği gerektirmeyen anestezi
- ❑ Komplikasyonlarla başetme
- ❑ İşlem akıcılığı; uygulayıcının konsantrasyonu

# ANESTEZİ YÖNTEMİNİ BELİRLEYEN FAKTÖRLER

- ❑ Çocuk hasta
- ❑ Rijit bronkoskopi
- ❑ Yandaş Hastalıklar
- ❑ Girişimsel işlemin niteliği



# FOB vs Rijit Bronkoskopi

- ❑ Yabancı cisim çıkarılması
- ❑ Masif hemoptizi kontrolü
- ❑ Bronkoskopik görüntü kalitesi
- ❑ Trakea darlığında FOB, hava geçişini engeller, ek solunum sıkıntısı
- ❑ Mekanik rezeksiyon, dilatasyon (stenoz)



Intubation with rigid bronchoscope



# Bronkoskopi göreceli kontrendikasyonları

## □ Göreceli kontrendikasyonlar

- **KVS hastalıklar (yakın zamanda geçirilmiş MI, stabil angina, aritmi, hipertansiyon)**
- **Serebrovasküler patoloji varlığı**
- **Kafa içi basınç yüksekliği**
- **Konvülziyon**
- **Kanama diatezi**
- **Trombositopeni (BAL<20.000/mm<sup>3</sup>, biyopsi 50.000 /mm<sup>3</sup>)**
- **Trombosit fonksiyon bozukluğu**
- **Ağır anemi**
- **Portal hipertansiyon**
- **Üremi**

# Bronkoskopi kontrendikasyonları-I

## □ Mutlak kontrendikasyonlar

- ✓ %100 oksijen uygulaması sonucu
- ✓  $\text{PaO}_2 < 60$  mmHg kalıyorsa
- ✓ Ağır bronkospazm
- ✓ Stabil olmayan astım

# ANESTEZİ YÖNTEMLERİ

**Lokal - Rejyonel Anestezi**

**Bilinçli Sedasyon**

**Genel Anestezi**


**TİVA - İnhalasyon**

# HASTA DEĞERLENDİRİLMESİ

HİPOKSEMI

• Solunum  
Fonksiyon Testi

- $FEV_1 < 1 \text{ L};$  % 35
- $FEV_1 < 1 - 1,5 \text{ L};$  % 7
- $FEV_1 > 1\text{L};$  % 7



$SpO_2$   
< % 90

# HASTA DEĞERLENDİRİLMESİ

## KARDİYAK RİSK

- Efor ??
- Eko
- Anjiyografi

- ❑ **FOB- sempatik yanıt- taşikardi, HT V/P bozukluk- BAL ile; Hipoksemi**
- ❑ **HİPOKSEMİ- ARİTMİ gelişiminde prediktör.**



# Monitorizasyon, Ekipman

## ❑ Kardiyopulmoner monitör

EKG, TA, SpO<sub>2</sub>, EtCO<sub>2</sub> (Transkütanöz, perkütan)

## ❑ Resüsitasyon düzeneği

ET, Laringoskop, İlaçlar


## ❑ Oksijen, aspiratör

## ❑ Bronkoskop ve yardımcı aletler




# Bronkoskopi Hazırlık

- ❑ **Açlık süresi**
- ❑ **Bilgilendirme: ONAM**
- ❑ **Hasta değerlendirme**
- ❑ **Premedikasyon**
- ❑ **Nebülizatör ile lokal anestezi uygulanır**  
**(%1 Lidokain, 5-7mL 10-15 dk)**



# LİDOKAİN TOPIKAL



- ❑ Atomizasyon, sprey
- ❑ Ultrasonik veya jet NEBULİZE LİDOKAİN : % 4 Lidokain
- ❑ Transkrikoid enjeksiyon
- ❑ Bronkoskop kanalından; ilerledikçe lidokain (% 1 veya 2 )



# LİDOKAİN REJYONAL BLOK

- ❑ Bilateral superiyor laringeal sinir bloğu
- ❑ Recurrent laringeal sinir (transtrakeal veya translaringeal blok)

- ✓ Zor hava yolu, FOB
- ✓ Farmakolojik ilaç kullanımından kaçınılması



# LİDOKAİN

- ❑ Plazma seviyelerini öngörmek zor
- ❑ Farmakokinetik etkileniyor: Süre, Suction sıklığı
- ❑ % 1 Lidokain kullanımı; The British Thoracic Society
- ❑ % 1-10 ; CHEST
- ❑ 8.2 mg/kg: max. doz

# TOKSİSİTEYİ ÖNLEME


- Renal ve hepatik disfonksiyonlu
- Havayolu inflamasyonlu
- Pediyatrik yaş grubu

**DOZ AZALTILMASI**

**KOMPLİKASYON ORANI % 0.09**

# LİDOKAİN

- ❑ Non-kardiyojenik pulmoner ödem
- ❑ Anafilaktik reaksiyon



## NADİR: AKILDA TUTULMALI



**Life-threatening Anaphylactic Reaction after the Administration of Airway Topical Lidocaine**

**Pediatric Pulmonology 46:505–508 (2011)**

**Acute Respiratory Distress Syndrome After Airway Anesthesia With Lidocaine**

**(*J Bronchol Intervent Pulmonol* 2010;17:245–247)**

# ATROPİN RUTİN KULLANIMI !?

## *Anticholinergic Agents*

17. Atropine and glycopyrrolate, when administered prebronchoscopy, do not produce a clinically meaningful improvement in lung function or decrease in bronchial secretions, and their use is discouraged.



CHEST

Consensus Statement

American College of Chest Physicians  
Consensus Statement on the Use of Topical  
Anesthesia, Analgesia, and Sedation During  
Flexible Bronchoscopy in Adult Patients

*CHEST* 2011; 140(5):1342–1350



# BİLİNÇLİ SEDASYON

	<b>Minimal sedasyon (anksiyoliz)</b>	<b>Orta derecede sedasyon/analjezi (bilinçli sedasyon)</b>	<b>Derin sedasyon/analjezi</b>	<b>Genel anestezi</b>
Yanıt verme	Sözlü uyarılara normal yanıt	Sözlü ve taktil uyarılara maksatlı* yanıt	Tekrarlayan veya ağrılı uyarılara maksatlı* yanıt	Ağrılı uyarılarla bile uyandırılmama
Havayolu	Etkilenmemiş	Müdahale gerektirmiyor	Müdahale Gerekebilir	Sıklıkla müdahale gerekir
Spontan solunum	Etkilenmemiş	Yeterli	Yetersiz olabilir	Sıklıkla yetersiz
Kardiyovasküler fonksiyon	Etkilenmemiş	Genellikle Korunuyor	Genellikle korunuyor	Bozulmuş olabilir

\* Ağrılı uyarana refleks geri çekme maksatlı yanıt kabul edilmemektedir.

*Gullo A. Sedation and anesthesia outside the operating room: definitions, principles, critical points and recommendations. Minerva anesthesiol 2005;71:1-9*

# BDZ ve OPIOİD

## MİDAZOLAM

- Anterograd amnezi
- Sedasyon
  - Hızlı etki başlangıcı
  - Hızlı pik etki
  - Kısa etki süresi

### *Yetişkin doz:*

0.06-0.07 mg/kg (0.5-2.5 mg IV)

### *Pediyatrik doz:*

0.05-0.2 mg/kg IV (max 0.6 mg/kg)

## FENTANİL

- Öksürüğü baskılma
- Analjezik etki
  - Hızlı etki başlangıcı
  - Hızlı pik etki
  - Kısa etki süresi

### *Yetişkin doz:*

25-50 mcg; 1-2 dk içinde

### *Pediyatrik doz:*

1-2 mcg/kg

# BDZ ve OPIOID' lerin tercih nedenleri

**Table 2—Reversal Agents for Benzodiazepines and Opioids**

Reversal Agent	Antagonized Drug	Metabolism	Excretion	Dosage and Administration	Onset of Action	Duration of Action	Special Considerations
Flumazenil	Benzodiazepines via the GABA benzodiazepine receptor	Hepatic	Renal	0.2 mg IV over 15 s, may repeat same dosage at 60-s intervals (maximum dosage: 1 mg/dose; 3 mg/h)	1-2 min	30-60 min	May lower seizure threshold in predisposed patient population; may cause benzodiazepine withdrawal in patients with chronic benzodiazepine use
Naloxone	Opioids via the opioids receptors ( $\mu$ , $\kappa$ , $\sigma$ )	Hepatic	Renal	0.1-0.2 mg IM/IV/SQ over 2-3 min (may need to repeat dosage relative to half life of opioids)	IV: 1-2 min IM/SQ: 2-5 min	1-4 h	May result in opioid withdrawal in patients with chronic narcotic use

GABA =  $\gamma$ -aminobutyric acid; SQ = subcutaneous.

# PROPOFOL

- Sedasyon**
- Anksiyolitik**
- Amnestik**

*Yetişkin doz:*

İndüksiyon: 0.1-0.15 mg/kg/dak.

İdame: 0.025-0.075 mg/kg/dak.

Etki başlangıç: 30-45 sn,

Etki süre 20-75 dak.

- Ciddi kardiyak disfonksiyon
- Propofol infüzyon sendromu

( $>5\text{mg/kg/h}$  , süre  $>48\text{h}$ )

- Metabolic asidosis, rabdomiyoliz, hiperkalemi, lipemi, hepatik, renal, kardiyak yetmezlik.

# REMİFENTANİL

- ❑ Ultra kısa etkili sentetik opioid
- ❑ Dose: 1 mcg/kg bolus  
0.05-0.2 mcg/kg/min
- ❑ Plazma esterazları ile metabolize olur
- ❑ Doza bağımlı; KAH, TA, SS ve TV azalır
- ❑ Rijitide

# DEXMEDETOMİDİNE

□ Alfa 2 agonist

□ Sedatif, Anksiyolitik, Analjezik, Sempatolitik

*Yetişkin doz:*

1 mcg/kg yükleme doz, süre: 10 dak içinde.

İdame: 0.2-1 mcg/kg/h idame.

□ **DESATÜRASYON**; - Remifentanilden daha az, recovery süresi daha uzun, LA gereksinimi yüksek, uygulayıcı memnuniyeti düşük

Ryu JH et al, Br J Anaesth. 2012 Mar;108(3):503-11

- **MİDAZOLAM** 'dan daha az,

Liao W et al. Journal of International Medical Research, 2012

□ **İŞLEME TOLERANS** ; MDZ dan daha iyi.

Pulmonary Medicine 2015

# BİLİNÇLİ SEDASYON AJANLAR

- ❑ DEX vs Midazolam PMC4620292, 2015
- ❑ DEX vs Sufentanil Clin Respir J 2014; 8: 100–107
- ❑ DEX vs DEX+KETA J Anaesth Clin Pharm 2014
- ❑ Propofol ve Remifentanil GA vs seda. Singapore Med J 2013
- ❑ Propofol vs Sevofluran Minerva Anesthesiol 2010;76:780-6)

Öksürük, hemodinamik stabilite

Hipoksemi- Desatürasyon

Uygulayıcı memnuniyeti

Sedasyon derecesi, hasta toleransı



T. Öztürk<sup>1</sup>  
A. Çakan<sup>2</sup>  
G. Gülerçe<sup>2</sup>  
G. Olgaç<sup>3</sup>  
S. Deren<sup>2</sup>  
A. Özsöz<sup>2</sup>

## Sedation for Fiberoptic Bronchoscopy: Fewer Adverse Cardiovascular Effects with Propofol than with Midazolam

Anaesthesiol Intensivemed Notfallmed Schmerzther 2014

FEV1 < % 50

**Propofol**  
Daha iyi hemodinami  
Benzer disritimi

Table 2. Hemodynamic parameters and incidence of arrhythmias during bronchoscopy with midazolam (M) or propofol (P) sedation

Phase of bronchoscopy	SpO <sub>2</sub>	Heart rate (beats/min)	Systolic BP (mm Hg)	Diastolic BP (mm Hg)	Major arrhythmias	
Before sedation	P	91.5 ± 1.8	97 ± 22	137 ± 22	97 ± 12	None
	M	92.8 ± 3.2	103 ± 22	144 ± 27	88 ± 11	None
After sedation	P	96.5 ± 1.8	92 ± 17	126 ± 20	81 ± 10	None
	M	96.5 ± 3.2	102 ± 20	130 ± 19	86 ± 9	None
At vocal cords	P	92.8 ± 4.2	107 ± 21	146 ± 26	91 ± 9	2 PVC
	M	91.3 ± 5.5	123 ± 17	164 ± 25	93 ± 8	None
During diagnostic procedure	P	94.7 ± 2.8	98 ± 15	129 ± 18	88 ± 6	2 PVC
	M	93.8 ± 2.8	113 ± 18	143 ± 22	90 ± 8	4 PVC 2 SVT
10 minutes after FOB	P	95.8 ± 1.8	95 ± 15	128 ± 16	88 ± 8	None
	M	95.8 ± 2.8	100 ± 17	137 ± 17	91 ± 7	None

**Fospropofol;** > 65 y hastalarda benzer sedasyonla ilgili advers olaylar ve hipoksemi sıklığı(% 26)

Fospropofol Disodium for Sedation in Elderly Patients Undergoing Flexible Bronchoscopy  
spropofol Disodium. J Bronchology Interv Pulmonol. 2011 Jan;18(1):15-22



# GENEL ANESTEZİ




Fig. 8 - Lowering of the tube through the mask.

Intubation with rigid bronchoscope



**İNHALASYON**



**SEVOFLURAN**

**TİVA**



**REMİ + KETA**  
**REMİ + PROPOFOL**  
**DEX + PROPOFOL**  
**DEX + REMİ**

**KAS GEVŞETİCİLİ veya KAS GEVŞETİCİSİZ**





# HİPOKSEMİ YÖNETİMİ

Yeterli oksijenizasyon

- Rijit bronkoskopi
- HFJV
- PEEP



MesH Vibrating  
Micropump  
Nebulizer



High Frequency Jet Ventilation in  
Interventional Fiberoptic Bronchoscopy:  
PRO+ALF



# KOMPLİKASYONLAR

- ❑ Disritmi
- ❑ Hemodinamik bozukluklar
- ❑ Hipoksemi
- ❑ Laringospazm-bronkospzm
- ❑ Öksürük
- ❑ Hemoptizi
- ❑ Barotravma
- ❑ LA Toksisitesi
- ❑ Kardiyak Arrest; % 0.07 Vazo-vagal senkop

% 0.08-6

**Table 3.** Severe complications of diagnostic bronchoscopy

Severe complications	n
Laryngospasm or tracheospasm or bronchospasm	30
Massive hemoptysis	28
Pneumothorax and/or subcutaneous emphysema	4
Cardiac arrhythmia	11
Total	73

**Table 4.** Severe complications of therapeutic bronchoscopy

Severe complications	n
Laryngospasm or tracheospasm or bronchospasm	38
Massive hemoptysis	9
Cardiac arrhythmia	13
Airway obstruction	8
Esophagotracheal fistula	5
Tracheal perforation	3
Death	3
Total	79

# KOMPLİKASYONLAR

**Table 5.** Severe complications of bronchoscopy

Procedure	Complications							
	death	laryngospasm or tracheospasm or bronchospasm	massive hemoptysis	cardiac arrhythmia	airway obstruction	esophago-tracheal fistula	pneumato-thorax and/or subcutaneous emphysema	racheal perforation
Bronchoscopic direct observation		10		1				
Endobronchial neoplasm or mucosal biopsy	1	10	<u>19</u>	2	1			
Lung tissue biopsy		2	<u>8</u>	1			4	
Endobronchial brushing		4		1				
Transbronchial biopsy		4	1	1				
Bronchoscopic suction of sputum		13						
Tracheal intubation via bronchoscope		9		4				
Bronchoscopic hemostasis				1				
Bronchoscopic retrieval of airway foreign body		1		1				
Microwave thermotherapy		10		2	2	2		2
Laser photoresection	2			2	<u>2</u>	<u>3</u>		<u>1</u>
Electrocautery			9	1	3			
Argon plasma coagulation		2		1	1			
Tracheobronchial stenting		2						
Balloon dilation		1		1				

# Effect of Acute Hypercapnia on Outcomes and Predictive Risk Factors for Complications among Patients Receiving Bronchoscopic Interventions under General Anesthesia

Qinghao Cheng<sup>1</sup>✉, Jieli Zhang<sup>2</sup>✉, Hongwu Wang<sup>2</sup>, Rujin Zhang<sup>3</sup>, Yun Yue<sup>4</sup>, Lei Li<sup>1</sup> \*

Acute Hypercapnia on Outcomes and Complications PLOS ONE DOI:10.1371/2015.11.8

Locations				
Trachea	11(13.3)	57(25.9)	15(31.9)	0.01
Bronchus	62(74.7)	60(31.1)	10(21.3)	0.00
Trachea+Bronchus	10(12.0)	76(39.4)	22(46.8)	0.00
Severe stenosis	11(13.3)	31(16.1)	15(31.9)	0.02

Data are presented as mean± standard deviation (median, range) or as a number (percentage).

Severe stenosis: diameter of trachea < 6 mm; the obstruction is above 90% of the main bronchus in a cross-sectional area. KPS: Karnofsky performance

**Grup C Kontrol: PaCO<sub>2</sub>: 60 mmHg**  
**Grup M: PaCO<sub>2</sub>:61–100 mmHg**  
**Grup S: PaCO<sub>2</sub>: >100 mmHg**

HFJV, RB içinden Fiber

GA: PROP+REMİ+ROCUR veya  
**SÜKSİNİL KOLİN**


**Table 3. Independent predictive factors for surgery complications.**

Complications	Independent predictive factor	Odds ratio(95% CI)	P
Postoperative congestive heart failure, tracheorrhagia, delayed recovery and transfer to ICU	Procedures duration*	0.079(0.028~0.13)	0.003
	Lobectomy	12.6(4.8~20.3)	0.007
	Dynamic airway collapse	15.6(3.5~27.8)	0.01
	Severe bronchial stenosis	7.56(1.55~13.57)	0.01
	Hypercapnia	3.21(2.3~ 7.6)	0.02



# BRONKOSKOPİ SONRASI SORUNLAR

- ❑ ÖKSÜRÜK
- ❑ LARİNGOSPAZM
- ❑ BRONKOSPAZM
- ❑ REAKTİF HAVA YOLU
- ❑ KANAMA



Buhar, hidrasyon, steroid, bronkodilatör

ATEŞ

PNÖMONİ

# BRONKOSKOPİ SONRASI SORUNLAR

## ÇOCUKTA UZUN SÜREN TEKRARLAYAN BRONKOSKOPİ

- Post glottik veya laringeal ödem
- Laringeal stridor
- Bronkospazm

Buhar, hidrasyon, steroid, bronkodilatör



# The effect of remifentanil on the emergence characteristics of children undergoing FBO for bronchoalveolar lavage with sevoflurane anaesthesia

Ozturk et al. European Journal of Anaesthesiology 2009, 26 :338-41

Table 2 Duration of bronchoscopy, anaesthesia, emergence and recovery (minutes) in children receiving sevoflurane (group S) or sevoflurane plus remifentanil (group SR) for diagnostic fiberoptic bronchoscopy

	Group S (n = 25)	Group SR (n = 25)	P <sup>a</sup>
Bronchoscopy	12 ± 3	10 ± 4	0.4
Anaesthesia	19 ± 4	18 ± 4	0.8
Emergence	10 ± 3	8 ± 2	0.1
Recovery	13 ± 4	7 ± 6	0.0001
EtSevo (%)	4.4 ± 0.8	3.8 ± 0.4	0.001
Remifentanil (µg)	-	22 ± 8	
Lidocaine (mg)	33 ± 6	32 ± 7	0.5
Midazolam (mg)	8 ± 2	8 ± 2	0.3

In addition, end-tidal sevoflurane concentrations (EtSevo) and total dose of medications used are given. Data are presented as mean ± SD. <sup>a</sup> Student's *t*-test.

Table 3 Coughing scores (median ± interquartile range) in children during the recovery period (at times 0, 5 min, 10 min, and 15 min) after having received sevoflurane (group S) or sevoflurane plus remifentanil (group SR) for diagnostic fiberoptic bronchoscopy

Times during recovery period	Group S (n = 25)	Group SR (n = 25)	P <sup>a</sup>
Time 0 (emergence)	0 ± 0.25	0 ± 0.75	0.06
Time 5 min <sup>c</sup>	1 ± 0.75	1 ± 1	0.27
Time 10 min <sup>c</sup>	1 ± 0.50	1 ± 1.25	0.77
Time 15 min	0 ± 1	0.5 ± 0.75	0.33
P <sup>b</sup>	<0.0001	0.3	

<sup>a</sup> Kruskal-Wallis ANOVA test. <sup>b</sup> Friedman ANOVA by ranks test. <sup>c</sup> P < 0.01 compared to time 0 (Wilcoxon matched pairs test, with level of significance re-adjusted).

# Effects of low-dose propofol vs ketamine on emergence cough in children undergoing flexible bronchoscopy with sevoflurane-remifentanil anesthesia: a randomised, double-blind, placebocontrolled trial. Ozturk et al. J Clin Anesth

**Table 3** Cough scores of 0/1 (<3 coughs/min) and 2/3 (≥3 coughs/min) in children during the recovery period (at times 0, 5 min, 10 min, 15 min, and 20 min) after diagnostic fiberoptic bronchoscopy.

	<b>Group Control (n=23) 0/1 : 2/3</b>	<b>Group Propofol (n=22) 0/1 : 2/3</b>	<b>Grup Ketamine (n=23) 0/1 : 2/3</b>	<i>P</i> <sup>a</sup>
<b>T0 (emergence)</b>	17 (74) : 6 (26)	17 (77) : 5 (23)	16 (70) : 7 (30)	0.8
<b>T5 min</b>	18 (78) : 5 (22)	16 (73) : 6 (27)	17 (74) : 6 (26)	0.9
<b>T10 min</b>	22 (96) : 1 (4)	18 (82) : 4 (18)	17 (74) : 6 (26)	0.1
<b>T15 min</b>	22 (96) : 1 (4)	18 (82) : 4 (18)	19 (83) : 4 (17)	0.3
<b>T20 min</b>	22 (96) : 1 (4)	21 (95) : 1 (5)	22 (96) : 1 (4)	1.0


Data are given as number (percentage)

<sup>a</sup> Pearson Chi-square test

# BRONKOSKOPİ SONRASI SORUNLAR

## PNÖMOTORAKS

- ❑ Lokal gaz trapping etkisi- **BAL**
- ❑ **Öksürük**- Transpulmoner basınç gradiyentinde artış
- ❑ Sürfarktan da azalma- **BAL** ile



Bilateral Pneumothorax After Bronchoscopy Without Biopsy—A Rare Complication: Case Presentation and Literature Review

*Setu Patolia, MD, Mehjabin Zahir, MD, Frances Schmidt, MD, Danilo Enriquez, MD,*

- ❑ **J Bronchol Intervent Pulmonol 2012;19:57–60**

# BRONKOSKOPI SONRASI SORUNLAR

## UVULADA NEKROZ



Fig. 1. The whitish-colored lower half of the uvula (arrow) is necrotic one day after bronchoscopy.




Fig. 2. Two weeks after bronchoscopy the necrotic portion of the uvula had detached from the upper half of the uvula (arrow).



# Sonuç

- Standart monitorizasyon
- Acil durumlara hazırlığı
- Hipokseminin önlenmesi
- Uygulayıcı ile perioperatif işbirliği

“Gemlik’e dođru denizi goreceksin, sakın řaşıırma”

O Veli



*Teřekkurler....*